AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA
Latest Information Update: 24 Jul 2024
At a glance
- Drugs PF-06835375 (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 Jul 2024 Planned End Date changed from 17 May 2027 to 27 Oct 2026.
- 19 Jul 2024 Planned primary completion date changed from 17 May 2027 to 27 Oct 2026.
- 23 Apr 2024 Planned End Date changed from 21 Mar 2025 to 17 May 2027.